Insulin Lispro
Insulin lispro (B28-Lys, B29-Pro human insulin analog)
51 Amino Acids · MW: 5808.0 Da
Amino Acids
51
Molecular Weight
5808.0 Da
Half-life
About 1 hour
Research Score
4.9
Studies
12000
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is Insulin Lispro?
A rapid-acting insulin analog with a reversed B28/B29 sequence that speeds absorption after subcutaneous injection. It is used to reduce postprandial hyperglycemia and to support flexible mealtime insulin strategies.
Key Benefits & Mechanisms
Rapid postprandial glucose control
Flexible premeal timing
Predictable onset of action
Useful in basal-bolus regimens
Research Summary
Clinical studies show faster onset and shorter duration than regular insulin, improving post-meal glucose control. It is a standard comparator in diabetes pharmacology and closed-loop insulin-delivery research.
Related Peptides
Insulin Aspart
Insulin aspart (B28-Asp human insulin analog)
A rapid-acting insulin analog with an amino-acid substitution at B28 that promotes faster absorption after injection. It is widely used to blunt postprandial glucose excursions in diabetes research and clinical practice.
Diabetes & MetabolicInsulin Glargine
Insulin glargine (A21Gly,B31Arg,B32Arg human insulin analog)
A long-acting basal insulin analog engineered for slow release from the subcutaneous depot. It provides relatively flat day-long insulin coverage and is used to control fasting glucose.
Diabetes & MetabolicInsulin Degludec
Insulin degludec (desB30, acylated ultra-long-acting insulin analog)
An ultra-long-acting insulin analog designed with a fatty-acid side chain to form a slow-release depot. It is valued for very flat pharmacokinetics and flexible once-daily basal dosing.
Diabetes & MetabolicExendin-4
Exendin-4 (synthetic exenatide)
A 39-amino-acid GLP-1 receptor agonist originally isolated from Heloderma saliva. It enhances glucose-dependent insulin secretion and shows strong beta-cell anti-apoptotic activity in preclinical diabetes models.
Diabetes & Metabolic